<DOC>
	<DOCNO>NCT02739828</DOCNO>
	<brief_summary>The objective study ass quality life ( QoL ) , skin pain , work productivity/activity health relate problem Swedish patient moderate severe HS 6 month treatment Adalimumab . The patient treat accordance normal routine clinical care .</brief_summary>
	<brief_title>Post Marketing Observational Study ( PMOS ) Assess Quality Life Swedish Hidradenitis Suppurativa ( HS ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Diagnosis Hidradenitis Suppurativa Prescribed Adalimumab accord Summary Product Characteristics ( SmPC ) Willingness sign date Patient Information/Informed Consent Form Prior biologic treatment discontinue &lt; 6 month baseline visit Patient able understand language provide patient questionnaire History noncompliance medication medical history could enhance noncompliance medication , determine investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Quality life</keyword>
</DOC>